Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 18008004)

1.

CD200 is induced by ERK and is a potential therapeutic target in melanoma.

Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE.

J Clin Invest. 2007 Dec;117(12):3922-9.

2.

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, Bhardwaj N.

Cancer Immunol Immunother. 2013 Apr;62(4):811-22. doi: 10.1007/s00262-012-1389-z. Epub 2013 Jan 10.

PMID:
23306863
3.

Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity.

Li Y, Zhao LD, Tong LS, Qian SN, Ren Y, Zhang L, Ding X, Chen Y, Wang YX, Zhang W, Zeng XF, Zhang FC, Tang FL, Zhang X, Ba DN, He W, Cao XT, Lipsky PE.

Arthritis Res Ther. 2012 May 23;14(3):R123. doi: 10.1186/ar3853.

4.

Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.

Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, Chien AJ.

Cell Cycle. 2012 Oct 15;11(20):3724-30. doi: 10.4161/cc.21645. Epub 2012 Aug 16.

5.

CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

Conticello C, Giuffrida R, Parrinello N, Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A, Romano A, Salomone E, Gulisano M, Giustolisi R, Di Raimondo F.

Leuk Res. 2013 Dec;37(12):1616-21. doi: 10.1016/j.leukres.2013.08.006. Epub 2013 Sep 23.

PMID:
24183830
6.

Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes.

Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L.

Immunol Lett. 2012 Aug 30;146(1-2):50-6. doi: 10.1016/j.imlet.2012.04.017. Epub 2012 May 2.

PMID:
22575528
7.

Kidins220/ARMS associates with B-Raf and the TCR, promoting sustained Erk signaling in T cells.

Deswal S, Meyer A, Fiala GJ, Eisenhardt AE, Schmitt LC, Salek M, Brummer T, Acuto O, Schamel WW.

J Immunol. 2013 Mar 1;190(5):1927-35. doi: 10.4049/jimmunol.1200653. Epub 2013 Jan 28.

8.

Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.

Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A.

Cancer Immunol Immunother. 2008 Jul;57(7):987-96.

PMID:
18060403
9.

Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.

Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F.

J Biol Chem. 2006 Apr 7;281(14):9238-50. Epub 2006 Feb 1.

10.

Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.

Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K, Hadjati J, Mirahmadian M, Jeddi-Tehrani M.

Tumour Biol. 2013 Feb;34(1):531-42. doi: 10.1007/s13277-012-0578-x. Epub 2012 Nov 18.

PMID:
23179394
11.

Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.

Yeh AH, Bohula EA, Macaulay VM.

Oncogene. 2006 Oct 26;25(50):6574-81. Epub 2006 May 22.

PMID:
16715137
12.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

13.

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.

Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.

14.

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.

Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, Schadendorf D.

PLoS One. 2007 Feb 21;2(2):e236.

15.

Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.

Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M.

Mol Cell Biol. 2001 May;21(9):3192-205.

16.

Effect of CD200 and CD200R1 expression within tissue grafts on increased graft survival in allogeneic recipients.

Yu K, Chen Z, Gorczynski R.

Immunol Lett. 2013 Jan;149(1-2):1-8. doi: 10.1016/j.imlet.2012.11.004. Epub 2012 Nov 21.

PMID:
23178470
17.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

18.

Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.

Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychène A, Mascarelli F.

J Biol Chem. 2003 Oct 24;278(43):42409-18. Epub 2003 Aug 12.

19.
20.

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.

Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, Brinckerhoff CE.

J Biol Chem. 2004 Aug 6;279(32):33168-76. Epub 2004 Jun 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk